What Happens When You Stop a GLP-1 Medication?

When you stop a GLP-1 medication, much of the weight tends to come back. In a study of FDA-approved semaglutide, people had regained about two-thirds of their loss a year after stopping, and most heart and metabolic improvements, including lower blood pressure, faded. A study of FDA-approved tirzepatide found a similar pattern, so plan any stop with your provider.

These findings come from research on FDA-approved products, not from Padgett patients, and they are not results for Padgett's personalized compounded semaglutide or personalized compounded tirzepatide. GLP-1 medicines act like GLP-1 (glucagon-like peptide-1), a natural hormone that helps regulate appetite; FDA-approved tirzepatide also acts like a second one, GIP, its label says.

How much weight comes back after you stop a GLP-1?

On average, much of it within a year, though not all of it. The STEP 1 trial extension tracked this directly. It followed 327 adults without diabetes who had spent 68 weeks on weekly FDA-approved semaglutide or a placebo, an inactive shot, along with lifestyle counseling every 4 weeks. Those on the medicine lost 17.3% of their body weight on average. Then the medicine and the counseling both stopped.

A year later, those who had taken the medicine had regained 11.6 percentage points, leaving them 5.6% below their starting weight on average. Regain was still under way at the last visit, though it seemed to slow toward the end. People who had lost the most tended to regain the most, yet still kept more of their loss overall. Almost half (48.2%) were still at least 5% lighter than when they started, compared with 22.6% of the placebo group.

Note the limits: the extension covered only part of the original trial, every analysis in it was exploratory, and, like the other two trials here, it was funded by the company that makes the medicine studied.

Does the same thing happen after stopping FDA-approved tirzepatide?

Yes, in the trial that tested it. In SURMOUNT-4, 783 adults without diabetes began 36 weeks of FDA-approved tirzepatide, with the dose raised step by step to the highest each could tolerate. The 670 who went on to the next phase had lost 20.9% of their weight on average. They were then randomly assigned to keep taking it or switch to a placebo for 52 more weeks, and everyone kept getting advice on a reduced-calorie diet and counseling to be active at least 150 minutes a week.

Over that year, the placebo group's weight rose 14.0% on average, while the group that stayed on the medicine lost another 5.5%. By the end, 89.5% of those who continued had kept at least 80% of their earlier loss, compared with 16.6% on placebo. From the very start, the placebo group still finished 9.9% below their starting weight, against 25.3% for those who stayed on it.

Can diet and exercise alone keep the weight off after you stop?

They may help, but in these trials they did not prevent regain on their own. Everyone in SURMOUNT-4 kept getting lifestyle counseling, and the placebo group still regained. STEP 4 showed the same thing with FDA-approved semaglutide: 803 adults lost 10.6% on average over 20 weeks, and with counseling continuing in both groups, those switched to a placebo saw their weight rise 6.9% over the next 48 weeks, while those who stayed on it lost another 7.9%.

That doesn't make habits pointless. NIDDK, part of the National Institutes of Health, says you will probably regain some weight after stopping a weight-management medicine, and that healthy eating and more physical activity may help you regain less or keep it off. The STEP 1 extension authors also suggested that losing the structured counseling may have added to how fast weight returned in their study. Habits that help keep the weight off and protein and muscle on a GLP-1 go further.

Do the health benefits fade when you stop?

Many of them do. In the STEP 1 extension, blood pressure rose after the medicine stopped and was back to its starting level a year later, and most other heart and metabolic measures drifted back toward where they began. Average blood sugar (HbA1c) rose too, but stayed slightly better than in the placebo group. Among people who started with prediabetes, 93.6% of those on the medicine had normal blood sugar at week 68, but only 43.3% did a year after stopping, against 34.0% in the placebo group.

SURMOUNT-4, as reported in the FDA-approved tirzepatide label, pointed the same way. During the first 36 weeks, systolic blood pressure (the top number) fell about 11 points and waists shrank about 7 inches. After the switch, the placebo group's systolic pressure rose about 8 points and their waists grew about 3 inches, while those who stayed on the medicine saw systolic pressure rise about 2 points and their waists keep shrinking.

Why does the weight come back after stopping?

Because the medicine's effect fades once it leaves your body, and obesity is a long-term condition. The FDA-approved labels for semaglutide and tirzepatide say both lower calorie intake, likely by acting on appetite. The FDA-approved semaglutide label puts its half-life, the time it takes for half of it to leave the blood, at about a week, and says it stays in circulation for about 5 to 7 weeks after the last maintenance dose. The FDA-approved tirzepatide label puts its half-life at about 5 days.

NIDDK describes obesity as a chronic disease, which is why, it says, new eating and activity habits may need to last for years, even a lifetime. The STEP 1 extension authors agreed: their results, they wrote, confirm that obesity is chronic and suggest that ongoing treatment is needed to keep the improvements in weight and health. They also noted that weight loss sets off biological changes that work against keeping it off; why most diets fail explains that pushback.

Should you stop a GLP-1 on your own?

No. Talk with your provider first, whatever the reason. NIDDK says that if you have lost enough weight to improve your health and have no serious side effects, your health care professional may advise staying on the medicine indefinitely. If you are not down at least 5% from your starting weight after 12 weeks on the full dose, it says the advice will probably be to stop.

Side effects can sometimes be handled short of stopping, and the options are your provider's call. When a dose isn't tolerated, the FDA-approved semaglutide label lets prescribers wait longer before the next increase, and the FDA-approved tirzepatide label allows a lower maintenance dose. Your provider may prescribe your weekly amount as two smaller injections, for example Monday and Thursday, when side effects call for it. Never change your schedule yourself. Splitting a tirzepatide dose twice a week explains the once-weekly schedule in the FDA-approved label, and managing GLP-1 side effects covers what else can help.

If cost is the reason, say so: pricing is by dose, and personalized compounded semaglutide without insurance lays out the prices. If your weight has stalled, that may simply be maintenance, which the FDA-approved labels list as a goal alongside losing excess weight; what a GLP-1 weight loss plateau means explains what to check.

Can you restart a GLP-1 after you stop?

Yes, if your provider decides it is still right for you. Restarting is a fresh prescribing decision, made at a visit that looks at how your weight, health and other medicines have changed since you stopped. Your provider also decides the dose you restart at, so don't restart leftover medicine or pick up your old dose on your own. If you have stopped and the scale is creeping up, call the clinic while the gain is still small.

How does stopping or restarting work at Padgett in Ocala?

You plan it with your provider. Visits are with Sarah Weir, APRN (advanced practice registered nurse), in person at 200 SW 8th St., Suite A, in Ocala, or by telehealth anywhere in Florida while you are physically in Florida. Before you stop, tell your provider at a visit or by calling the clinic. Your provider reviews your progress, side effects, goals and budget, then decides with you whether to stay on, change the dose or stop.

Personalized compounded semaglutide starts at $149 a month and personalized compounded tirzepatide at $229 a month, at the starting dose. Each is a medically supervised weekly injection, shipped to your door in Florida, and your provider personalizes the dose and adjusts it over time. The monthly price is your medication. Your provider visit is $100 and is free when you start medication at that visit; the only other charge is a $50 no-show fee. There are no contracts.

If a weekly injection no longer fits your life, ask about phentermine weight loss in Ocala, an FDA-approved generic appetite suppressant pill and Schedule IV controlled substance, labeled for short-term use alongside a reduced-calorie diet, exercise and behavior change. Your provider decides whether it is safe for you.

Book a weight-loss visit in person or by telehealth; nothing is charged when you book. Questions first? Ask for a free 15-minute phone call with the medical staff; it is not a visit with the provider and nothing is prescribed on it. Or call the clinic at (352) 369-0104.

Personalized compounded semaglutide and personalized compounded tirzepatide are compounded drugs that have not been approved by the FDA. They have not been reviewed by the FDA for safety, effectiveness, or quality. FDA-approved products containing semaglutide and tirzepatide are available. Individual results vary.

This article is educational and is not medical advice. Talk with a licensed provider about your own health, medications and treatment options.